Trial Profile
Treatment with aflibercept for AMD cases with better value in optometry
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms TAABO
- 09 Jun 2015 Status changed from planning to recruiting, as reported by UMIN record.
- 13 Nov 2013 New trial record